Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 | Shoals Technologies Group | SELL $5 | ― | -24.10% | Assigned | Shoals Technologies Group Sell Recommendation Amid Patent Litigation Concerns and Margin Pressures | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $65 | ― | 20.50% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $39→$37.25 | ― | 14.20% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $280→$255 | ― | 10.40% | Downgraded | ||||
 | WalkMe | BUY $19 | ― | -6.50% | Reiterated | WalkMe (WKME) Receives a Buy from JMP Securities | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $38→$25 | ― | 0.80% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $292 | ― | 2.20% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $2→$1 | ― | 1.70% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $123→$138 | ― | 16.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $228 | ― | 3.60% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $40→$37 | ― | 6.50% | Downgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $12 | ― | 7.80% | Assigned | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $50 | ― | 13.60% | Assigned | ||||
 | Waystar Holding Corp. | BUY $24 | ― | -5.70% | Initiated | Waystar Holding Corp. (WAY) Receives a New Rating from Barclays | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $760 | ― | 1.90% | Initiated | ||||
 | AbSci | BUY $7 | ― | -14.90% | Initiated | Buy Rating on AbSci: AI/ML Innovation, Strong Partnerships, and Attractive Valuation Present Investment Opportunity | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $34 | ― | 11.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $21 | ― | 3.40% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $211 | ― | 14.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $32 | ― | 7.90% | Reiterated | ||||
| Baidu | BUY $135 | ― | -24.80% | Assigned | Baidu's Strategic Focus and ROIC Improvement Justify Buy Rating | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $46 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $42 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $220 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $150 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $90 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $92 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $194 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $18 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $91 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $504 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45 | ― | 12.40% | Assigned | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $42 | ― | 6.60% | Initiated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $17→$12 | ― | 4.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 19.00% | Downgraded | ||||
| Versus Systems | HOLD $1.5→$2 | ― | -17.00% | Reiterated | Versus Systems: Hold Rating Amidst Management Shift and Restructuring Risks | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $190 | ― | 5.00% | Reiterated | ||||
 | Abeona Therapeutics | BUY $15 | ― | -1.40% | Initiated | Buy Rating Affirmed for Abeona Therapeutics on Promising pz-cel Therapy for RDEB | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5 | ― | 4.60% | Upgraded | ||||
| Tyra Bioscience | BUY $23 | ― | -16.70% | Reiterated | Buy Rating Affirmed for Tyra Bioscience on TYRA-300's Promising Preclinical Efficacy and Strategic Development Plans | |||
| Cartesian Therapeutics | BUY $54→$49 | ― | -16.70% | Reiterated | Buy Rating Affirmed for Cartesian Therapeutics on Descartes-08's Promising Clinical Trial Results | |||
| Kyverna Therapeutics, Inc. | HOLD $8 | ― | -16.70% | Initiated | Hold Rating on Kyverna Therapeutics Amid Efficacy Concerns and Rising Competition in CAR-T Landscape | |||
| Assertio Therapeutics | BUY $4 | ― | -1.40% | Initiated | Assertio Holdings initiated with a Buy at H.C. Wainwright | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $115→$92 | ― | 5.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $67 | ― | 9.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $341→$325 | ― | 19.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25→$28 | ― | 13.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $9 | ― | 11.30% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $160→$248 | ― | 6.20% | Reiterated |
Rows:
